ETNHX Performance — Eventide Healthcare & Life Sciences Fund, Class N
Data updated: 2026-09-11
ETNHX returned +12.09% year to date and +71.36% over one year to Jun 2026. Annualised returns are +15.54% over 3 years and +6.55% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $154, against $138 for the category, and to $171 over one year, against $137. Volatility over the past three years was 24.53% a year. In the 12 months to Jun 2026 the fund lost a net $140.3M, and assets reached $1.79B.
ETNHX Growth of $100
What $100 invested in Eventide Healthcare & Life Sciences Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | ETNHX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $171 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $154 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $137 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $189 | $182 |
ETNHX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +12.09% |
| 1 year | +71.36% |
| 3 years (annualised) | +15.54% |
| 5 years (annualised) | +6.55% |
ETNHX Annual Returns
Calendar-year total returns of Eventide Healthcare & Life Sciences Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +12.09% |
| 2025 | +56.40% |
| 2024 | −10.31% |
| 2023 | +10.78% |
| 2022 | −19.78% |
| 2021 | −16.75% |
| 2020 | +36.73% |
| 2019 (Jul–Dec) | +18.75% |
ETNHX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −2.0% | +0.7% | −3.5% | +5.2% | 0.0% | +11.8% | — | — | — | — | — | — |
| 2025 | +7.9% | −4.7% | −9.7% | +3.3% | −1.2% | +7.9% | +4.9% | +10.3% | +5.1% | +13.2% | +13.3% | −1.9% |
| 2024 | −2.6% | +7.7% | −0.3% | −12.3% | +0.6% | −0.3% | +8.5% | +0.8% | −2.2% | −1.2% | +2.0% | −9.5% |
| 2023 | +6.3% | −2.2% | −5.4% | +7.1% | +4.0% | +3.1% | +0.1% | −6.4% | −5.8% | −9.4% | +4.1% | +17.7% |
| 2022 | −18.5% | −3.8% | −2.1% | −15.8% | −3.6% | +4.9% | +7.9% | +9.6% | −3.8% | +1.8% | +1.2% | +4.9% |
| 2021 | −4.5% | +3.9% | −6.9% | −0.9% | −7.8% | +0.4% | −5.0% | +10.1% | −0.4% | +1.0% | −9.1% | +2.7% |
| 2020 | −5.2% | −7.0% | −13.4% | +16.6% | +15.6% | +2.1% | −6.3% | +7.4% | +1.6% | +8.6% | +12.3% | +4.5% |
| 2019 | — | — | — | — | — | — | −1.7% | −8.8% | −9.5% | +8.3% | +23.7% | +9.3% |
ETNHX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 24.53%
- 3-year Sharpe ratio: 0.45 (vs 4.5% risk-free rate)
- Best month: +17.73% (Dec 2023)
- Worst month: −12.35% (Apr 2024)
ETNHX Fund Flows
Monthly money in and out of Eventide Healthcare & Life Sciences Fund, from SEC Form N-PORT.
- 12-month net flow: −$140.3M
- 12-month gross sales (incl. reinvestments): $532.7M
- Sales ÷ redemptions: 0.79×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $61.7M | $78.0M | −$16.3M |
| May 2026 | $19.4M | $48.8M | −$29.4M |
| Apr 2026 | $21.4M | $45.6M | −$24.3M |
| Mar 2026 | $77.6M | $87.1M | −$9.5M |
| Feb 2026 | $32.9M | $26.7M | $6.2M |
| Jan 2026 | $26.2M | $44.0M | −$17.8M |
| Dec 2025 | $114.2M | $117.1M | −$2.9M |
| Nov 2025 | $29.4M | $37.0M | −$7.6M |
| Oct 2025 | $36.3M | $30.5M | $5.8M |
| Sep 2025 | $20.6M | $36.0M | −$15.4M |
| Aug 2025 | $74.7M | $86.8M | −$12.1M |
| Jul 2025 | $18.2M | $35.3M | −$17.1M |
ETNHX Assets Under Management
Net assets of Eventide Healthcare & Life Sciences Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $1.79B |
| 2026-03-31 | $1.59B |
| 2025-12-31 | $1.69B |
| 2025-09-30 | $1.35B |
| 2025-06-30 | $1.15B |
| 2025-03-31 | $1.12B |
| 2024-12-31 | $1.29B |
| 2024-09-30 | $1.49B |
| 2024-06-30 | $1.44B |
| 2024-03-31 | $1.72B |
| 2023-12-31 | $1.67B |
| 2023-09-30 | $1.56B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.